Cover Image
Market Research Report

Biodefense Market Size, Share & Trends Analysis Report By Product (Anthrax, Smallpox, Botulism, Radiation/Nuclear), By Region (North America, Europe, APAC, Latin America, MEA), And Segment Forecasts, 2020 - 2027

Published by Grand View Research, Inc. Product code 963207
Published Content info 100 Pages
Delivery time: 2-3 business days
Price
Back to Top
Biodefense Market Size, Share & Trends Analysis Report By Product (Anthrax, Smallpox, Botulism, Radiation/Nuclear), By Region (North America, Europe, APAC, Latin America, MEA), And Segment Forecasts, 2020 - 2027
Published: September 29, 2020 Content info: 100 Pages
Description

Biodefense Market Growth & Trends

The global biodefense market size is expected to reach USD 19.9 billion by 2027, expanding at a CAGR of 5.9%, according to a new report by Grand View Research, Inc. Biodefense can be briefly defined as comprehensive measures (identification, planning, and preparedness) taken to rehabilitate the biosecurity of a country concerning biological threats or infectious diseases that can be easily used as a bioweapon to instigate social destruction and bioterrorism. Biological threats can be naturally occurring, accidental, or deliberate in origin. Factors like the presence of favorable government initiatives, increasing investment by private players, and the growing prevalence of various viral agents are fueling the market growth.

Previous incidents of bioterrorism caused by viral agents like anthrax, smallpox, botulism have made biodefense a major focus area for advancements by countries to prevent bioterrorism. In 2017, the Centre for Disease Control and Prevention (CDC) stated that they had tracked more than 170 unique diseases globally and also identified outbreaks in more than 190 countries. In addition, according to the WHO, around 6, 50,000 people die of respiratory diseases associated with seasonal flu annually. Repeated outbreaks of the Zika and Ebola virus have coerced state governments to construct and strategize biodefense programs that will assist in planning and responding during future outbreaks. In 2018, the U.S government announced and issued the National Biodefense Strategy to manage the risk of biological incidents by detecting and containing biothreats at its source, promoting biomedical innovation, and improving emergency response. These factors are expected to boost market growth over the forecast period.

Biodefense Market Report Highlights

The anthrax segment dominated the market in 2019. These bioagents possess a high risk of the threat, can last long in the environment, and can be released easily into the environment

Others product segment which includes Zika, Ebola and Marburg's virus is expected to reciprocate highest CAGR over the forecast period due to rising outbreaks of diseases

North America dominated the market in 2019 owing to the presence of high federal funding, technological advancements, and growing awareness among the population

Asia Pacific is expected to reciprocate the highest CAGR over the forecast period owing to growing investment in R&D activities and the increasing threat of biowarfare.

Table of Contents
Product Code: 978-1-68038-313-3

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation & Scope
    • 1.1.1 Product
    • 1.1.2 Regional Scope
    • 1.1.3 Estimates And Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 Gvr's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details Of Primary Research
  • 1.4 Information Or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis (Model 1)
  • 1.7 List Of Secondary Sources
  • 1.8 List Of Primary Sources
  • 1.9 List Of Abbreviations
  • 1.10 Objectives
    • 1.10.1 Objective - 1:
    • 1.10.2 Objective - 2:
    • 1.10.3 Objective - 3:
    • 1.10.4 Objective - 4:

Chapter 2 Executive Summary

  • 2.1 Market Outlook

Chapter 3 Biodefense Market: Variables, Trends, & Scope

  • 3.1 Market Segmentation And Scope
  • 3.2 Market Dynamics
    • 3.2.1 Market Driver Analysis
    • 3.2.2 Presence Of Favorable Government Initiatives In The U.S.
      • 3.2.2.1 Biodefense Funding In Fy 2016-2019 By Federal Agency
      • 3.2.2.2 Emergency Use Authorization Of Medical Products
      • 3.2.2.3 Project Bioshield Act
      • 3.2.2.4 Growing Investment From Private Players
    • 3.2.3 Growing Prevalence Of Various Agents Such As Ebola Virus, Zika Virus, Flu, And Others
    • 3.2.4 Market Restraint Analysis
      • 3.2.4.1 Low Market Penetration In Developing And Underdeveloped Countries
  • 3.3 Penetration & Growth Prospect Mapping
  • 3.4 Biodefense: Market Analysis Tools
    • 3.4.1 Industry Analysis - Porter's
    • 3.4.2 Pestel Analysis
  • 3.5 Biodefense Competitive Scenario, 2015
    • 3.5.1 Biological Defense
      • 3.5.1.1 Biological Defense: Product Pipeline
    • 3.5.2 Chemical Defense
      • 3.5.2.1 Chemical Defense: Product Pipeline
    • 3.5.3 Nuclear/Radiological Defense
      • 3.5.3.1 Nuclear/Radiological Defense: Product Pipeline Analysis

Chapter 4 Biodefense Market: Product Segment Analysis

  • 4.1 Biodefense: Agent Market Share Analysis, 2019 & 2027
  • 4.2 Anthrax
    • 4.2.1 Biodefense Against Anthrax Market Estimates And Forecasts, 2016 - 2027 (USD Million)
  • 4.3 Smallpox
    • 4.3.1 Biodefense Against Smallpox Market Estimates And Forecasts, 2016 - 2027 (USD Million)
  • 4.4 Botulism
    • 4.4.1 Biodefense Against Botulism Market Estimates And Forecasts, 2016 - 2027 (USD Million)
  • 4.5 Radiation/Nuclear
    • 4.5.1 Biodefense Against Radiation/Nuclear Market Estimates And Forecasts, 2016 - 2027 (USD Million)
    • 4.5.2 Others
      • 4.5.2.1 Other Biodefense Products Market Market, 2016 - 2027 (USD Million)

Chapter 5 Biodefense Market: Regional Analysis

  • 5.1 Biodefense: Regional Market Share Analysis, 2019 & 2027
  • 5.2 North America
    • 5.2.1 North America Biodefense Market, 2016 - 2027 (USD Million)
    • 5.2.2 U.S.
      • 5.2.2.1 U.S. Biodefense Market, 2016 - 2027 (USD Million)
    • 5.2.3 Canada
      • 5.2.3.1 Canada Biodefense Market, 2016 - 2027 (USD Million)
  • 5.3 Europe
    • 5.3.1 Europe Biodefense Market, 2016 - 2027 (USD Million)
    • 5.3.2 U.K.
      • 5.3.2.1 U.K. Biodefense Market, 2016 - 2027 (USD Million)
    • 5.3.3 Germany
      • 5.3.3.1 Germany Biodefense Market, 2016 - 2027 (USD Million)
    • 5.3.4 France
      • 5.3.4.1 France Biodefense Market, 2016 - 2027 (USD Million)
    • 5.3.5 Italy
      • 5.3.5.1 Italy Biodefense Market, 2016 - 2027 (USD Million)
    • 5.3.6 Spain
      • 5.3.6.1 Spain Biodefense Market, 2016 - 2027 (USD Million)
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Biodefense Market, 2016 - 2027 (USD Million)
    • 5.4.2 China
      • 5.4.2.1 China Biodefense Market, 2016 - 2027 (USD Million)
    • 5.4.3 India
      • 5.4.3.1 India Biodefense Market, 2016 - 2027 (USD Million)
    • 5.4.4 Japan
      • 5.4.4.1 Japan Biodefense Market, 2016 - 2027 (USD Million)
  • 5.5 Latin America
    • 5.5.1 Latin America Biodefense Market, 2016 - 2027 (USD Million)
    • 5.5.2 Brazil
      • 5.5.2.1 Brazil Biodefense Market, 2016 - 2027 (USD Million)
    • 5.5.3 Mexico
      • 5.5.3.1 Mexico Biodefense Market, 2016 - 2027 (USD Million)
    • 5.5.4 Argentina
      • 5.5.4.1 Argentina Biodefense Market, 2016 - 2027 (USD Million)
  • 5.6 Mea
    • 5.6.1 Mea Biodefense Market, 2016 - 2027 (USD Million)
    • 5.6.2 South Africa
      • 5.6.2.1 South Africa Biodefense Market, 2016 - 2027 (USD Million)

Chapter 6 Company Profiles

  • 6.1 Xoma Corporation
    • 6.1.1 Company Overview
    • 6.1.2 Financial Performance
    • 6.1.3 Product Benchmarking
    • 6.1.4 Strategic Initiatives
  • 6.2 Altimmune, Inc.
    • 6.2.1 Company Overview
    • 6.2.2 Financial Performance
    • 6.2.3 Product Benchmarking
    • 6.2.4 Strategic Initiatives
  • 6.3 Emergent Biosolutions Inc.
    • 6.3.1 Company Overview
    • 6.3.2 Financial Performance
    • 6.3.3 Product Benchmarking
    • 6.3.4 Strategic Initiatives
  • 6.4 Dynavax Technologies Corporation
      • 6.4.1company Overview
    • 6.4.2 Financial Performance
    • 6.4.3 Strategic Initiatives
  • 6.5 Siga Technologies, Inc.
    • 6.5.1 company Overview
    • 6.5.2 Financial Performance
    • 6.5.3 Product Benchmarking
    • 6.5.4 Strategic Initiatives
  • 6.6 Elusys Therapeutics, Inc.
    • 6.6.1 company Overview
    • 6.6.2 Financial Performance
    • 6.6.3 Product Benchmarking
    • 6.6.4 Strategic Initiatives
  • 6.7 Ichor Medical Systems
    • 6.7.1 Company Overview
    • 6.7.2 Financial Performance
    • 6.7.3 Product Benchmarking
    • 6.7.4 Strategic Initiatives
  • 6.8 Dynport Vaccine Company Llc
    • 6.8.1 company Overview
    • 6.8.2 Financial Performance
    • 6.8.3 Product Benchmarking
    • 6.8.4 Strategic Initiatives
  • 6.9 Cleveland Biolabs
    • 6.9.1 Company Overview
    • 6.9.2 Financial Performance
    • 6.9.3 Product Benchmarking
    • 6.9.4 Strategic Initiatives
  • 6.10 Bavarian Nordic
    • 6.10.1 Company Overview
    • 6.10.2 Financial Performance
    • 6.10.3 Product Benchmarking
    • 6.10.4 Strategic Initiatives
  • 6.11 Ology Bioservices
      • 6.11.1company Overview
    • 6.11.2 Financial Performance
    • 6.11.3 Product Benchmarking
    • 6.11.4 Strategic Initiatives
  • 6.12 Alnylam Pharmaceuticals, Inc.
    • 6.12.1 Company Overview
    • 6.12.2 Financial Performance
    • 6.12.3 Product Benchmarking
    • 6.12.4 Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviation
  • Table 3 U.S. government civilian biodefense funding, by agencies for the years 2017-2019 in USD Million.
  • Table 4 National Institutes of Health Funding for the years 2017-2019 in USD Million
  • Table 5 Travel Associated cases of Zika Virus in the U.S in 2019
  • Table 6 Ebola Funding to WHO, 2019

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Commodity flow analysis
  • Fig. 9 Biodefense market snapshot (2019)
  • Fig. 10 Biodefense market segmentation
  • Fig. 11 Market driver relevance analysis (Current & future impact)
  • Fig. 12 Market restraint relevance analysis (Current & future impact)
  • Fig. 13 Penetration & growth prospect mapping
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 16 Biodefense market product type outlook: Segment dashboard
  • Fig. 17 Biodefense market: Product movement analysis
  • Fig. 18 Anthrax market, 2016 - 2027 (USD Million)
  • Fig. 19 Smallpox market, 2016 - 2027 (USD Million)
  • Fig. 20 Botulism market, 2016 - 2027 (USD Million)
  • Fig. 21 Radiation/Nuclear market, 2016 - 2027 (USD Million)
  • Fig. 22 Others market, 2016 - 2027 (USD Million)
  • Fig. 23 Regional market: Key takeaways
  • Fig. 24 Regional outlook, 2019 & 2027
  • Fig. 25 North America market, 2016 - 2027 (USD Million)
  • Fig. 26 U.S. market, 2016 - 2027 (USD Million)
  • Fig. 27 Canada market, 2016 - 2027 (USD Million)
  • Fig. 28 Europe market, 2016 - 2027 (USD Million)
  • Fig. 29 U.K. market, 2016 - 2027 (USD Million)
  • Fig. 30 Germany market, 2016 - 2027 (USD Million)
  • Fig. 31 France market, 2016 - 2027 (USD Million)
  • Fig. 32 Italy market, 2016 - 2027 (USD Million)
  • Fig. 33 Spain market, 2016 - 2027 (USD Million)
  • Fig. 34 Asia Pacific market, 2016 - 2027 (USD Million)
  • Fig. 35 China market, 2016 - 2027 (USD Million)
  • Fig. 36 India market, 2016 - 2027 (USD Million)
  • Fig. 37 Japan market, 2016 - 2027 (USD Million)
  • Fig. 38 Latin America market, 2016 - 2027 (USD Million)
  • Fig. 39 Brazil market, 2016 - 2027 (USD Million)
  • Fig. 40 Mexico market, 2016 - 2027 (USD Million)
  • Fig. 41 Argentina market, 2016 - 2027 (USD Million)
  • Fig. 42 MEA market, 2016 - 2027 (USD Million)
  • Fig. 43 South Africa market, 2016 - 2027 (USD Million)
Back to Top